



PiT2 deficiency prevents increase of bone marrow adipose tissue during skeletal maturation but not in OVX-induced osteoporosis

Giulia Frangi, Marie Guicheteau, Frederic Jacquot, Grzegorz Pyka, Greet Kerckhofs, Magalie Feyeux, Joëlle Veziers, Pierre Guihard, Boris Halgand, Sophie Sourice, et al.

► To cite this version:

Giulia Frangi, Marie Guicheteau, Frederic Jacquot, Grzegorz Pyka, Greet Kerckhofs, et al.. PiT2 deficiency prevents increase of bone marrow adipose tissue during skeletal maturation but not in OVX-induced osteoporosis. *Frontiers in Endocrinology*, 2022, 13, <10.3389/fendo.2022.921073>. <hal-03899764>

HAL Id: hal-03899764

<https://hal.science/hal-03899764v1>

Submitted on 27 Nov 2023

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



HAL Authorization



OPEN ACCESS

EDITED BY

Jonathan H Tobias,
University of Bristol, United Kingdom

REVIEWED BY

William Peter Cawthorn,
University of Edinburgh,
United Kingdom
Nicola J Lee,
The University of Sydney, Australia

*CORRESPONDENCE

Sarah Beck-Cormier
sarah.beck@univ-nantes.fr

†PRESENT ADDRESSES

Marie Guicheteau,
Nantes Université, CNRS, INSERM,
l'institut du thorax, Nantes, France
Laurent Beck,
Nantes Université, CNRS, INSERM,
l'institut du thorax, Nantes, France
Sarah Beck-Cormier,
Nantes Université, CNRS, INSERM,
l'institut du thorax, Nantes, France

SPECIALTY SECTION

This article was submitted to
Bone Research,
a section of the journal
Frontiers in Endocrinology

RECEIVED 15 April 2022

ACCEPTED 24 October 2022

PUBLISHED 16 November 2022

CITATION

Frangi G, Guicheteau M, Jacquot F,
Pyka G, Kerckhofs G, Feyeux M,
Veziers J, Guihard P, Halgand B,
Sourice S, Guicheux J, Prieur X, Beck L
and Beck-Cormier S (2022) PiT2
deficiency prevents increase of
bone marrow adipose tissue during
skeletal maturation but not in
OVX-induced osteoporosis.
Front. Endocrinol. 13:921073.
doi: 10.3389/fendo.2022.921073

PiT2 deficiency prevents increase of bone marrow adipose tissue during skeletal maturation but not in OVX-induced osteoporosis

Giulia Frangi¹, Marie Guicheteau^{1†}, Frederic Jacquot²,
Grzegorz Pyka^{3,4}, Greet Kerckhofs^{3,4,5,6}, Magalie Feyeux⁷,
Joëlle Veziers¹, Pierre Guihard¹, Boris Halgand¹,
Sophie Sourice¹, Jérôme Guicheux¹, Xavier Prieur⁸,
Laurent Beck^{1†} and Sarah Beck-Cormier^{1*†}

¹Nantes Université, Oniris, CHU Nantes, Inserm, Regenerative Medicine and Skeleton, RMeS, UMR 1229, SFR Bonamy, Nantes, France, ²Nantes Université, CHU Nantes, Inserm, CNRS, CRCI2NA, Nantes, France, ³Biomechanics lab, Institute of Mechanics, Materials, and Civil Engineering, UC Louvain, Louvain-la-Neuve, Belgium, ⁴Department of Materials Engineering, KU Leuven, Leuven, Belgium, ⁵IREC, Institute of Experimental and Clinical Research, UC Louvain, Woluwé-Saint-Lambert, Belgium, ⁶Prometheus, Division of Skeletal Tissue Engineering, KU Leuven, Leuven, Belgium, ⁷Nantes Université, CHU Nantes, CNRS, Inserm, BioCore, US16, SFR Bonamy, Nantes, France, ⁸Nantes Université, CNRS, Inserm, l'Institut du Thorax, Nantes, France

The common cellular origin between bone marrow adipocytes (BMAd) and osteoblasts contributes to the intimate link between bone marrow adipose tissue (BMAT) and skeletal health. An imbalance between the differentiation ability of BMSCs towards one of the two lineages occurs in conditions like aging or osteoporosis, where bone mass is decreased. Recently, we showed that the sodium-phosphate co-transporter PiT2/SLC20A2 is an important determinant for bone mineralization, strength and quality. Since bone mass is reduced in homozygous mutant mice, we investigated in this study whether the BMAT was also affected in *PiT2*^{-/-} mice by assessing the effect of the absence of PiT2 on BMAT volume between 3 and 16 weeks, as well as in an ovariectomy-induced bone loss model. Here we show that the absence of PiT2 in juveniles leads to an increase in the BMAT that does not originate from an increased adipogenic differentiation of bone marrow stromal cells. We show that although *PiT2*^{-/-} mice have higher BMAT volume than control *PiT2*^{+/+} mice at 3 weeks of age, BMAT volume do not increase from 3 to 16 weeks of age, leading to a lower BMAT volume in 16-week-old *PiT2*^{-/-} compared to *PiT2*^{+/+} mice. In contrast, the absence of PiT2 does not prevent the increase in BMAT volume in a model of ovariectomy-induced bone loss. Our data identify *SLC20a2/PiT2* as a novel

gene essential for the maintenance of the BMAd pool in adult mice, involving mechanisms of action that remain to be elucidated, but which appear to be independent of the balance between osteoblastic and adipogenic differentiation of BMSCs.

KEYWORDS

PiT2/Slc20a2, adipocytes, bone, post-menopausal osteoporotic mouse model, marrow

Introduction

Bone marrow adipose tissue (BMAT) is no longer considered a marrow space filler tissue as the increasing number of studies on its function in the past 20 years has highlighted its important roles in skeletal health or energetic metabolism. However, the underlying cellular and molecular mechanisms involved remain to be determined (1–3). In mice, bone marrow adipocytes (BMAds) first develop in the distal tibia at a very early postnatal age and then appear in the proximal tibia at around 3 months of age (3, 4). The volume of BMAT increases with age in humans and mice, turning the bone marrow from “red” to “yellow”. The proximal and distal BMAT are two distinct tissues mainly because the size and the lipidic components of the adipocytes are different, and both are differentially regulated (5). The proximal BMAT is also referred to as regulated BMAT (rBMAT) due to the observation that its volume is regulated by several physiopathological conditions (caloric restriction, cold exposure...), whereas the distal one is referred to as constitutive BMAT (cBMAT) because volume variations of this tissue are less frequently observed.

A growing interest in BMAT and its intimate relationship with skeletal health has emerged in recent years. Inverse correlation between BMAT volume and bone mass has been described in many situations (5) and also in some genetic mouse models (6–11). However, this negative correlation is not always observed and may even be controversial, as in the ovariectomy-induced osteoporosis model (7, 11). In healthy populations, BMAT increases with age both in men and women, with men generally having more BMAT (12, 13), and an inverse correlation between BMAT volume and bone mineral density (BMD) has been described (14–17). Nevertheless, during puberty, the amount of marrow fat is positively associated with total bone mineral content in girls (18) and, although men have more BMAT mass compared to women, they also have more bone mass (19). These observations highlight a complex relationship between BMAT and bone, which probably cannot be described in all circumstances as a simple inverse correlation.

Nonetheless, the relationship between BMAT and bone is based at least on the fact that osteoblasts and BMAds are both

derived from bone marrow stromal cells (BMSCs). The imbalance between the differentiation capacities of BMSCs towards one of the two lineages is at the origin of the increased bone marrow adiposity in conditions like aging, obesity and other pathologies where the bone mass is decreased (11, 20, 21) and a better knowledge of the underlying mechanisms would allow a better understanding of the balancing relationship between bone and BMAT.

PiT2 is a member of the Slc20 family of sodium (Na)-phosphate (Pi) co-transporters, encoded by the *Slc20a2* gene. In the last 10 years, numerous studies have revealed the multifunctionality of PiT1/SLC20A1 and PiT2/SLC20A2 in the regulation of cellular proliferation, differentiation or survival (22–30). In bone, our group and others have shown the involvement of PiT2 in bone quality, mineralization and strength (31, 32). Homozygous mutant mice were shown to exhibit severe reduction of bone mechanical properties (decreased yield load, maximum load, fracture load and stiffness), reduced bone mineral density and reduced bone mass (31, 32). Considering the deleterious effect of PiT2 deficiency in bone, we questioned whether the BMAT could also be affected in PiT2 knockout mice. In addition, we evaluated the effect of the absence of PiT2 on the regulation of bone and BMAT volumes between 3 and 16 weeks and in a model of ovariectomy-induced bone loss.

Materials & methods

Mice

C57BL/6NTac-Slc20a2tm11a (EUCOMM) Wtsi (*Slc20a2*^{+/-}, hereafter named *PiT2*^{+/-}) heterozygous mice were obtained from the European Mouse Mutant Archive (EMMA) and maintained and genotyped at Nantes Université. Experiments on mice were conducted according to the French and European regulations on care and protection of laboratory animals (EC Directive 86/609, French Law 2001-486 issued on June 6, 2001). This study complied with ARRIVE (Animal Research: Reporting of *In Vivo* Experiments) guidelines and was approved by the Animal Care

Committee of Pays de la Loire (APAFIS agreements 02286.02, 14835-2020-05-13 and 22178-2019092614593965 v7). Animal care and maintenance were provided through the Nantes Université accredited animal facility at the “Unité de Thérapeutique Expérimentale” (UTE). Mice were housed under specific pathogen-free conditions in open or individually ventilated cages, with wood shavings for bedding and nesting material, in groups of up to five. The mice had *ad libitum* access to tap water and standard rodent chow (A04-10; SAFE, France). Genotyping was performed by PCR as described (31). Wild-type ($PiT2^{+/+}$) and $PiT2^{-/-}$ littermate mice were analysed at 3 and 16 weeks. Three-week-old mice were used for *in vitro* experiments (adipogenic differentiation, flow cytometry). Ovariectomy (OVX) was performed under isoflurane anesthesia in 13-week-old female $PiT2^{+/+}$ and $PiT2^{-/-}$ littermate mice, which were euthanized 5 weeks later. $PiT2^{+/+}$ and $PiT2^{-/-}$ mice were randomly allocated to two groups: an OVX group and a sham group (mice were similarly incised but the ovaries were not removed). Mice were anesthetized with ketamine/xylazine administered intraperitoneally and were perfused transcardially with Phosphate Buffered Saline (PBS) and then 4% Paraformaldehyde (PFA; Sigma Aldrich, USA). Uterine aplasia was observed, confirming the successful ovariectomy. Right tibiae were removed and fixed in 4% PFA for 24 hours at 4°C and stored in PBS at 4°C for the subsequent CE-CT analyses.

Contrast-enhanced high resolution microfocus computed tomography

Before polyoxometalate-staining (33), the distal end of the bones was removed to allow better diffusion of the contrast agent into the bone marrow compartment. Samples were incubated in the staining solution during 48 hours at 4°C while shaking gently.

CE-CT acquisition and image processing were performed as previously described (33, 34). Briefly, samples were imaged using a Phoenix Nanotom S (GE Measurement and Control Solutions, Germany) and analysed using DataViewer (Bruker MicroCT, Belgium) for the reorientation of the CE-CT datasets and CTAn (Bruker MicroCT) for the assessment of the fat volume in the proximal and distal tibiae. Ad.V relative to Ma.V (bone marrow without trabecular and cortical bones) was determined at 2-μm resolution in a 2mm (proximal) or 4mm (distal) region beginning right underneath the growth plate. Segmentation and morphological assessment of adipocytes was performed as previously described (33).

For bone volume fraction (BV/TV %) and Cortical thickness (Ct.th. mm) analyses, we used an in-house developed semi-automated protocol. Volumes of interest around the trabecular bone region were drawn in the proximal metaphysis starting

directly underneath growth plate and covering a height of 1.2mm distal to the growth plate. Cortical thickness was determined in a mid-diaphyseal volume of interest starting 1mm proximal of the tibio-fibular junction, extending 1mm in the proximal direction.

BMSCs culture

BMSCs were harvested from tibiae of 3-week-old $PiT2^{-/-}$ and $PiT2^{+/+}$ mice. After removing the epiphyses, bones were flushed to isolate total bone marrow cells and BMSCs were expanded in growth media consisting of α -MEM (Eurobio, France) supplemented with 15% fetal bovine serum (FBS), 100IU/mL penicillin, 100mg/mL streptomycin, 2mM glutamine. At confluence, BMSCs were cultured in adipogenic media consisting of α -MEM (Eurobio, France) supplemented with 15% FBS, 100IU/mL penicillin, 100mg/mL streptomycin, 2mM glutamine, 0.5μM 3-isobutyl-1-methylxanthine (IBMX), 0.5μM hydrocortisone and 60μM indomethacin (Sigma Aldrich).

Oil Red O staining and relative quantification

Cells were fixed in 2% PFA for 15min, washed with water, incubated with 60% isopropanol for 5min and stained with newly filtered Oil Red O solution for 10min at room temperature. To quantify staining, Oil Red O was extracted from the cells with isopropanol and absorbance of the solution was measured at a wavelength of 520nm to determine the relative amount of dye. Determination of the number of adipocytes (Oil Red O positive cells) and the number of total cells (Hoechst positive cells) was performed by using the High Content Screening Arrayscan (ThermoScientific). Image acquisitions (361 images per well) were performed using the Cellomics ArrayScan VTI/HCS Reader (ThermoScientific) using x5 magnification. Images analysis was performed with CellProfiler (35).

Flow cytometry

Flow cytometry was performed on a BD LSRFortessa™ (BD Biosciences), FACS data were collected using DIVA (Becton Dickinson) and analysed using FlowJo software (Tree Star). For flow cytometry analyses, BMSCs were isolated by flushing tibiae of P21 mice, flushed bones were crushed with a mortar and treated with collagenase for 20min at 37°C to retrieve any remaining BMSCs. The reaction was stopped by adding α -MEM complemented with 15% FBS and the cell suspension was passed through a 70μm cell strainer (BD Falcon, MA, USA)

to remove bone fragments. The cells were then added to the previously flushed bone marrow with isolated BMSCs. Cells were centrifuged at 1200rpm for 5min at RT, the pellet was resuspended in Red Blood Cell Lysis Buffer (Sigma, Product No. R 7757) to eliminate red blood cells and centrifuged again at 1200rpm for 5min at RT. The pellet was resuspended and the cells were counted. Five million cells were stained with antibodies (Supporting Table S1) for 30min on ice. Compensation was performed using OneComp™ eBeads Compensation Beads (ThermoFisher Scientific Inc.). BMSCs were analysed as Ter119⁻ CD45⁻ Sca1⁺ CD44⁺ CD105⁺ (36, 37) and adipogenic progenitors as Ter119⁻ CD45⁻ CD31⁻ Sca1⁺ CD24⁻ (38).

RNA isolation and RT-qPCR

Total RNA was prepared with TRIzol Reagent (ThermoFisher Scientific) according to the manufacturer's instructions. The RNA was reverse transcribed and analysed on a Bio-Rad CFX96 detection system using SYBR Select Master Mix (Applied Biosystems, Warrington, UK). mRNA levels were normalized relative to beta-glucuronidase (*GusB*) and Pinin (*Pnn*) expression and quantified using the $\Delta\Delta CT$ method (39). RT-qPCR primers were: Pinin Forward (Fw)-ACCTGG AAGGGGCGAGTCAGTA and Reverse (Rv)-ATCATCGT CTTCTGGGTCGCT, *GusB* Fw-CTCTGGTGGCCTT ACCTGAT and Rv- CAGTTGTTGTACCTTCACCTC, *Pit1* Fw-TGTGGCAAATGGGCAGAAG and Rv-AGAAA GCAGCGGAGAGACGA, *Pit2* Fw-CCATCGGCT TCTCACTCGT and Rv AAACCAGGAGGCGACAATCT, *FABP4* Fw-GAATTTCGATGAAATCACCGCA and Rv-CTCTTTATTGTGGTGCAGTTTCCA, *AdipoQ* Fw- TCTCCT GTTCCTCTTAATCCTGCC and Rv-CATCTCCTTT CTCTCCCTTCTCTC.

Statistics

Statistical analyses were performed using the GraphPad 8.0 software. Data were analysed for normal distribution within each experimental group using the Shapiro–Wilk normality test. Normally distributed data were analysed by ANOVA or t tests, as appropriate. Where data were not normally distributed, non-parametric tests were used. When appropriate, *p* values were adjusted for multiple comparisons as indicated in the figure legends. A *p* value of less than 0.05 was considered statistically significant (exact *n* and *p* values are indicated in the figures or legends). Data are expressed as means \pm S.E.M. Units and abbreviations are reported in accordance with recently published guidelines for research relating to BM adiposity (40).

Results

Proximal BMAT volume does not increase in *Pit2*^{-/-} mice between 3 and 16 weeks

Bone marrow adipose tissue was investigated by using Hf-POM-based CE-CT analysis on tibiae from 3- and 16-week-old *Pit2*^{+/+} and *Pit2*^{-/-} littermate mice. The 3D visualization and quantification of the bone marrow adipocytes showed an increase in BMAT volume within the proximal tibia of 3-week-old *Pit2*^{-/-} female (Figure 1A, Supplementary Figure 1) and male (Supplementary Figure 2A, Supplementary Figure 3) mice compared to *Pit2*^{+/+} mice, which is consistent with the increased mRNA gene expression of *Adiponectin* (*AdipoQ*) and *FABP4* (Figure 1B, Supplementary Figure 2B), two markers of mature adipocytes. The absence of *Pit2* mRNA expression was confirmed in whole tibia from *Pit2*^{-/-} mice by RT-qPCR (Figure 1B, Supplementary Figure 2B). Interestingly, no difference in the expression of the paralog *Pit1* mRNA expression was observed in *Pit2*^{-/-} whole tibia, making a possible *Pit1*-driven compensatory mechanism unlikely (Figure 1B, Supplementary Figure 2B).

In contrast to *Pit2*^{+/+} mice, CE-CT analyses showed that BMAT volumes did not increase between 3 and 16 weeks in the proximal tibia of *Pit2*^{-/-} mice, both in females (Figure 1A), and males, (Supplementary Figure 2A), leading to a downward trend in BMAT volume at 16 weeks in *Pit2*^{-/-} compared to wild-type mice. This illustrates the possibility that the absence of *Pit2* blunts the age-induced BMAT increase that is normally observed in the proximal tibiae of wild-type mice. Interestingly, in contrast to proximal tibiae, the increase in distal BMAT between 3 and 16 weeks was not affected by the absence of *Pit2* at least in female (Figure 1C, not determined in males), suggesting a specific role for *Pit2* in the proximal BMAT.

Lack of *Pit2* does not alter BMSCs adipogenic differentiation

BMADs originate from the adipogenic differentiation of bone marrow stromal cells. To investigate the ability of *Pit2*-deficient BMSC to differentiate into adipocytes, we first quantified the adipogenic progenitors and explored the adipogenic differentiation capacity of BMSCs. We quantified these cells as Ter119⁻ CD45⁻ Sca1⁺ CD44⁺ CD105⁺ cells by flow cytometry. The results showed no difference in the proportion of BMSCs in 3-week-old *Pit2*^{-/-} female samples compared to *Pit2*^{+/+} mice (Figure 2A). Moreover, similar to BMSCs, analyses of adipogenic progenitors sorted as Ter119⁻ CD45⁻ CD31⁻ Sca1⁺ CD24⁻ cells, showed that the proportion of adipogenic progenitors in *Pit2*^{-/-} female mice was equal to that of *Pit2*^{+/+} mice (Figure 2A).




FIGURE 1

Deregulation of BMAT volume in *Pit2*^{-/-} female mice. **(A)** Upper - Representative 3D visualization, using Hf-POM-based CE-CT, of the adipocytes in the bone marrow compartment of the proximal tibia of 3- and 16-week-old *Pit2*^{+/+} and *Pit2*^{-/-} female mice. Scale bar = 250 μ m. Lower - Graphs showing quantification of the volume fraction of the adipocytes in the VOI of the proximal tibia (Ad.Ar/Ma.Ar: Adipocyte area/Marrow Area) of 3- and 16-week-old *Pit2*^{+/+} and *Pit2*^{-/-} mice ($n=6$ and 12 per genotype, respectively). Data are means \pm SEM, Bonferroni-corrected Mann-Whitney test. p values are indicated. **(B)** Relative *Pit1*, *Pit2*, *Adiponectin* and *FABP4* mRNA expression in the whole tibia from 3- ($n=7$ *Pit2*^{+/+} and $n=4-6$ *Pit2*^{-/-}) and 16- ($n=8$ *Pit2*^{+/+} and $n=11$ *Pit2*^{-/-}) week-old *Pit2*^{+/+} and *Pit2*^{-/-} female mice, as indicated. Data are means \pm SEM, Mann-Whitney test, $**p < 0.01$. **(C)** Upper - Representative 3D visualization of the adipocytes in the bone marrow compartment of the distal tibia of 3- and 16-week-old *Pit2*^{+/+} and *Pit2*^{-/-} female mice. Lower - Graphs showing quantification of the volume fraction of the adipocytes in the VOI of the distal tibia of 3- and 16-week-old *Pit2*^{+/+} and *Pit2*^{-/-} mice ($n=6$ and 11 per genotype, respectively). Data are means \pm SEM, the influence of age or genotype, and interactions between these, was determined by two-way ANOVA, with p values shown to the right of the graph. p values from multiple comparisons are indicated on the graph.

Adipogenic differentiation analyses of BMSCs isolated from tibiae of 3-week-old *Pit2*^{-/-} and *Pit2*^{+/+} mice did not show differences between mutant and *Pit2*^{+/+} cells from female and male mice, neither by quantification of Oil Red O positive cells nor by *Adiponectin* and *FABP4* mRNA expression analyses (Figures 2B–D, Supplementary Figure 4). Similar to what is

observed *in vivo*, *Pit1* mRNA expression showed no differences between *Pit2*^{-/-} and *Pit2*^{+/+} cells (Figure 2D and Supplementary Figure 4B). Altogether, these results revealed that lack of *Pit2* expression did not alter BMSCs populations or adipogenic differentiation, despite aberrant regulation of proximal BMAT in mutant mice.




FIGURE 2

Characteristics of BMSCs in *Pit2*^{-/-} mice. **(A)** FACS quantification of BMSCs (Ter119⁻ CD45⁻ Sca1⁺ CD44⁺ CD105⁺) (Left) and adipogenic progenitors (Ter119⁻ CD45⁻ CD31⁻ Sca1⁺ CD24⁺) (Right) in the bone marrow of tibiae from 3-week-old *Pit2*^{+/+} and *Pit2*^{-/-} female mice (n=6 per genotype). Data are means ± SEM, Mann-Whitney test. **(B)** Representative images of oil-red O (ORO) positive cells after adipogenic differentiation of *Pit2*^{+/+} and *Pit2*^{-/-} BMSCs. Scale bar = 100μm. **(C)** Quantitative analysis of ORO+ cells: Left, percentage of ORO+ cells related to the total number of Hoechst-positive cells; right, ORO absorbance at 520nm. **(D)** Relative *Pit2*, *Pit1*, *Adiponectin* and *FABP4* mRNA expression at 0 (n=12 *Pit2*^{+/+} and n=9 *Pit2*^{-/-}), 7 (n=7 *Pit2*^{+/+} and n=4 *Pit2*^{-/-}) and 14 (n=4 *Pit2*^{+/+} and n=4 *Pit2*^{-/-}) days of differentiation. N=3 independent experiments. Data are means ± SEM. Two-way ANOVA test.

Regulation of bone and BMAT volumes in $PiT2^{-/-}$ mice after ovariectomy (OVX)

To evaluate the regulation of bone and BMAT volumes, 13-week-old $PiT2^{-/-}$ female mice and their control littermate ($PiT2^{+/+}$) were subjected to OVX-induced osteoporosis. Five weeks after surgery, animals were analyzed for bone and BMAT volumes by CE-CT. Results show that sham-operated $PiT2^{-/-}$ female mice have similar trabecular BV/TV as $PiT2^{+/+}$ control mice, while cortical thickness was significantly reduced (Figure 3A), consistent with our previous study (31). In OVX mice, we showed a similar reduction in trabecular BV/TV and Ct.Th. in wild-type and $PiT2^{-/-}$ mice (Figure 3A). This reduction in bone volume parallels an increase in BMAT volume observed both in ovariectomized $PiT2^{+/+}$ and

$PiT2^{-/-}$ mice compared with sham-operated controls (fold-change: 2.65 and 3.22, respectively; Figure 3B). Of note, sham-operated $PiT2^{-/-}$ mice showed a reduced BMAT volume compared with sham-operated $PiT2^{+/+}$ mice (Figure 3B), consistent with our observation in 16-week-old females (Figure 1A). These findings indicate that bone and BMAT volumes are inversely regulated in the model of ovariectomy-induced bone loss, and suggest that $PiT2$ -deficient adipocytes retain the ability to be recruited after OVX.

Discussion

In the present study, we report for the first time a role for $PiT2$ in the maintenance of bone marrow adipose tissue volume.




FIGURE 3

$PiT2$ deficiency does not prevent BMAT volume increase and bone mass loss after ovariectomy. (A) Bone volume/tissue volume (BV/TV, left) and cortical thickness (Ct.th., right) of tibia from sham operated mice ($n=12$ $PiT2^{+/+}$ and $n=7$ $PiT2^{-/-}$) or after ovariectomy (OVX, $n=16$ $PiT2^{+/+}$ and $n=10$ $PiT2^{-/-}$) quantified using CE-CT images. Data are means \pm SEM, Bonferroni-corrected Mann-Whitney test (BV/TV) and two-way ANOVA test (Ct.Th.). For Ct.Th., the influence of surgery or genotype, and interactions between these, was determined by two-way ANOVA, with p values shown to the right of the graph. p values from multiple comparisons are indicated on the graphs (B) Left: representative 3D visualization, using Hf-POM-based CE-CT, of adipocytes in the bone marrow compartment of the proximal tibia (2mm height from the growth plate) of $PiT2^{+/+}$ and $PiT2^{-/-}$ female mice after ovariectomy (OVX). Right: graphs showing the quantification of the volume fraction of the adipocytes in the VOI of the proximal tibia (Ad.Ar/Ma.Ar: Adipocyte area/Marrow Area) in sham operated mice ($n=12$ $PiT2^{+/+}$ and $n=7$ $PiT2^{-/-}$) or after ovariectomy (OVX, $n=16$ $PiT2^{+/+}$ and $n=10$ $PiT2^{-/-}$). Data are means \pm SEM, Bonferroni-corrected Mann-Whitney test.

We also show that BMSCs with or without PiT2 are able to differentiate into adipocytes in an identical manner, suggesting that the regulation of proximal BMAT volume by PiT2 does not involve cell autonomous mechanisms.

Increased BMAT volume in young $PiT2^{-/-}$ mice

An increase in marrow adipocytes which inversely parallels a loss of bone volume is observed in numerous genetic models (6, 8, 10). This link between bone and BMAT volumes cross-regulation is based on either the balance between osteo-adipogenic differentiation of BMSC or the secreted factors from bone cells or BMAdS which can act on the surrounding tissue (6, 8, 10, 41). Our previous work showed that bone mass in young (3-week-old) $PiT2^{-/-}$ mice was reduced compared to $PiT2^{+/+}$ mice (31), and we now show, conversely, that proximal BMAT volume is higher compared with wild-type mice. Although this is consistent with the expected inverse cross-regulation between bone and adipocyte volumes, we nevertheless show that adipogenic differentiation of PiT2-deficient BMSCs is not altered. However, the *in vitro* adipogenesis conditions used in our study may be so potent that they override any subtle differences in BMSC adipogenic potential that exist *in vivo*. In addition, the use of more sensitive technologies, such as single cell RNA sequencing, the use of other recently identified adipogenic progenitor markers could help to identify other *in vivo* stromal populations that modulate adipogenesis and whose expression may be abnormal in $PiT2^{-/-}$ mice (42–45). To date we have not identified which cellular or molecular mechanism affected by the loss of PiT2 deregulates adipocyte volume control. However, we interestingly observed that proximal BMAdS can be detected at least from 16 days of age (not shown) in the $PiT2^{-/-}$ mice, which is very early compared to the appearance of proximal BMAT in wild-type mice that can only be observed from 4 weeks of age in C57Bl/6 (46). This may therefore suggest that PiT2 deletion affects cellular or molecular pathways that occur during development or very early after birth and may provide an invaluable study model to identify them.

No inverse correlation between BMAT and bone volumes in adult $PiT2^{-/-}$ mice

In adult $PiT2^{-/-}$ mice, the reduced bone mass is not associated with an increased BMAT volume compared to $PiT2^{+/+}$ mice. As we have shown previously, the bone defects in mutant mice are independent of osteoblast or osteoclast number or activity (31), supporting the hypothesis that BMAT and bone defects in the absence of PiT2 are not generated by a coupling imbalance between adipocytes and osteoblasts differentiation.

BMAT volume is known to be regulated by several hormones (e.g., PTH, estrogen or FSH) (2, 3). However, we

have previously shown that serum PTH levels were similar between $PiT2^{+/+}$ and $PiT2^{-/-}$ mice, excluding its role in the genesis of the phenotype (47). In post-menopausal women, BMAT volume is highly increased and ovariectomy is now a commonly used approach to increase BMAT volume in animal models (7, 10, 34, 48, 49). Estrogen, in addition to be a negative regulator of BMAdS, is a positive regulator of the bone mass (48). These opposite effects of estrogen on bone and fat tissues may be explained by the imbalanced ability of BMSCs to differentiate into osteoblasts in favor of adipocytes, although no direct evidence has yet been obtained. In $PiT2^{-/-}$ mice, both bone and BMAT volumes are reduced and a similar phenotype is observed in males, ruling out the possibility that a defect in estrogen levels could explain the phenotype of these mutant mice. Hence, further studies will be needed to identify the possible systemic factor underlying the alterations in bone and marrow adipose tissues.

Bone and bone marrow adipose tissues are sensitive to estrogen depletion in $PiT2^{-/-}$ mice

The observation that BMAT volume does not increase between 3 and 16 weeks in $PiT2^{-/-}$ mice led us to question the regulation of bone and adipose tissue volumes in pathological conditions. In ovariectomized $PiT2^{-/-}$ mice, we showed that bone mass is decreased and that this is accompanied by BMAT accumulation similar to that in control mice. These results suggest that in the absence of PiT2 adipogenic differentiation is not affected and that the mechanisms that govern it are upstream of PiT2-dependent pathways. On the other hand, it is well documented that OVX-induced bone loss is primarily caused by induction of bone resorption. Here, we show that bone loss is similar in OVX- $PiT2^{+/+}$ mice and OVX- $PiT2^{-/-}$ mice, indicating that osteoclast formation and activity are not impaired, consistent with our previous findings that showed normal osteoclast activity in $PiT2^{-/-}$ mice (31). The lack of effect of PiT2 deletion on bone and fat phenotypes during ovariectomy is consistent with the fact that we do not observe differences in male and female mutant mice. As these results were obtained in adult mice, they may also support the idea that the role of PiT2 in the bone and BMAT phenotypic balance occurs earlier in the development or during the growth of the animal.

Could phosphate homeostasis explain the BMAT phenotype in $PiT2^{-/-}$ mice?

As one of the major cellular functions of PiT2 is to transport phosphate across the plasma membrane, it is reasonable to ask whether the observed phenotype of $PiT2^{-/-}$ mice may be phosphate-related. In the literature, a link between phosphate and adipose tissues is rarely reported, either in extra- or intra-

medullar adipose tissues. In humans, an inverse correlation between serum Pi levels and obesity has been observed, and an association between high phosphate diet and the suppression of lipogenesis in white adipose tissue has been described both in humans and rodents (50–57). Interestingly, acute phosphate restriction in mice decreases bone formation and results in an increase in BMAT due to defects in the commitment of BMSC preferentially towards the adipogenic lineage involving the Wnt signaling pathway (58, 59). It is therefore possible that a change in phosphate homeostasis may impact the balance between bone formation and BMAT. However, *PiT2*^{-/-} mice show no differences in serum phosphate levels and key markers of phosphate homeostasis regulation (31, 32, 60, 61), precluding a role for serum phosphate in the BMAT defects observed in the absence of *PiT2*. However, as we hypothesize for the dental defects in the *PiT2*^{-/-} mice (62), the local extracellular Pi level, rather than the serum Pi levels, may be responsible for the observed phenotype. Interestingly, invalidation of *Phospho1*, another phosphate-related gene, results in a reduction in bone volume and bone mineral density, along with an increase in BMAT volume (63, 64). Whether this phenotype is directly due to an abnormal local level of Pi within the skeleton or whether it is an indirect consequence of modified energy metabolism remains to be determined.

In summary, we have shown that loss of *PiT2* leads to defects in bone and marrow adipose tissues, probably through a non-intrinsic defect of osteoblasts, osteoclasts and BMAds, leading to impaired bone quality and strength. Further identification is needed to decipher the underlying cellular mechanisms.

Data availability statement

The original contributions presented in the study are included in the article/**Supplementary Materials**. Further inquiries can be directed to the corresponding author.

Ethics statement

Experiments on mice were conducted according to the French and European regulations on care and protection of laboratory animals (EC Directive 86/609, French Law 2001-486 issued on June 6, 2001). This study complied with ARRIVE (Animal Research: Reporting of In Vivo Experiments) guidelines and was approved by the Animal Care Committee of Pays de la Loire (APAFIS agreements 02286.02, 14835-2020-05-13 and 22178-2019092614593965 v7).

Author contributions

Study design: GF, LB, and SB-C. Data collection: GF, MG, GP, PG, GK, MF, JV, BH, SS and SB-C. Data analysis and

interpretation: GF, MG, GP, GK, MF, XP, LB and SB-C. Drafting manuscript: GF, LB and SB-C. Revising manuscript content: GF, MG, JG, XP, LB and SB-C. Approving final version of manuscript: all authors. SBC takes responsibility for the integrity of the data analysis.

Funding

This work was supported by grants from Inserm, Region des Pays de la Loire (AdipOs) and Société Française de Rhumatologie (PITAMO and METABONE). GF and MG received a doctoral fellowship from Nantes Université.

Acknowledgments

The authors are grateful to the Experimental Health core facility (PES) and SC3M histology facility of the SFR Bonamy (Nantes, France) for their technical support, and MicroPiCell and Cytocell facilities (UMS BioCore, Inserm US16/CNRS UAR3556) for expert technical assistance. The authors gratefully acknowledge Carla Geeroms (Department of Materials Engineering, KU Leuven, Leuven, BELGIUM), Céline Menguy (Inserm U1087, Nantes, France) and Séverine Marionneau (Inserm U1232, Nantes) for technical help. The authors also gratefully acknowledge Dr Christophe Chauveau (MABLab, Boulogne-sur-mer, France) and Dr Céline Colnot (IMRB, Paris) for helpful discussions.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: <https://www.frontiersin.org/articles/10.3389/fendo.2022.921073/full#supplementary-material>

SUPPLEMENTARY FIGURE 1

Three-D visualization, using Hf-POM-based CE-CT, of the adipocytes in the bone marrow compartment of the proximal tibia of 3-week-old $Pit2^{+/+}$ and $Pit2^{-/-}$ female mice.

SUPPLEMENTARY FIGURE 2

Deregulation of BMAT volume in $Pit2^{-/-}$ male mice. (A) Upper - Representative 3D visualization, using Hf-POM-based CE-CT, of the adipocytes in the bone marrow compartment of the proximal tibia (2mm height from the growth plate) of 3- and 16-week-old $Pit2^{+/+}$ and $Pit2^{-/-}$ male mice. Lower - Graph showing quantification of the volume fraction of the adipocytes in the proximal tibia $Pit2^{+/+}$ and $Pit2^{-/-}$ mice at 3 weeks (n=5 and 3, respectively) and 16 weeks (n=6 and 5, respectively). Data are means \pm SEM, Bonferroni-corrected Mann-Whitney test. (B) Relative *Pit1*, *Pit2*, *Adiponectin* and *FABP4* mRNA expression in the whole tibia from 3- (n=5 per genotype) and 16- (n= 7 $Pit2^{+/+}$ and n= 5 $Pit2^{-/-}$)

week-old $Pit2^{+/+}$ and $Pit2^{-/-}$ male mice, as indicated. Data are means \pm SEM, Mann-Whitney test, * $p < 0.05$.

SUPPLEMENTARY FIGURE 3

Three-D visualization, using Hf-POM-based CE-CT, of the adipocytes in the bone marrow compartment of the proximal tibia of 3-week-old $Pit2^{+/+}$ and $Pit2^{-/-}$ male mice.

SUPPLEMENTARY FIGURE 4

Adipogenic differentiation of BMSCs from $Pit2^{-/-}$ males. (A) Left - Representative images of $Pit2^{+/+}$ and $Pit2^{-/-}$ BMSCs after adipogenic differentiation and ORO staining. Scale bar = 100 μ m. Right - Graphs showing the percentage of oil-red O (ORO) positive cells related to the total number of Hoechst-positive cells (left) and ORO absorbance at 520nm (right). (B) Relative *Pit1*, *Adiponectin* and *FABP4* mRNA expression at 0 and 7 days of differentiation, n are indicated on graph bars. Data are means \pm SEM, Mann-Whitney test.

References

- de Paula FJA, Rosen CJ. Marrow adipocytes: Origin, structure, and function. *Annu Rev Physiol* (2020) 82:461–84. doi: 10.1146/annurev-physiol-021119-034513
- Li Z, Hardij J, Bagchi DP, Scheller EL, MacDougald OA. Development, regulation, metabolism and function of bone marrow adipose tissues. *Bone* (2018) 110:134–40. doi: 10.1016/j.bone.2018.01.008
- Sebo ZL, Rendina-Ruedy E, Ables GP, Lindskog DM, Rodeheffer MS, Fazeli PK, et al. Bone marrow adiposity: Basic and clinical implications. *Endocr Rev* (2019) 40:1187–206. doi: 10.1210/er.2018-00138
- Scheller EL, Cawthorn WP, Burr AA, Horowitz MC, MacDougald OA. Marrow adipose tissue: Trimming the fat. *Trends Endocrinol Metab* (2016) 27:392–403. doi: 10.1016/j.tem.2016.03.016
- Tratwal J, Labella R, Bravenboer N, Kerckhofs G, Douni E, Scheller EL, et al. Reporting guidelines, review of methodological standards, and challenges toward harmonization in bone marrow adiposity research. report of the methodologies working group of the international bone marrow adiposity society. *Front Endocrinol (Lausanne)* (2020) 11:65. doi: 10.3389/fendo.2020.00065
- Fan Y, Hanai JI, Le PT, Bi R, Maridas D, DeMambro V, et al. Parathyroid hormone directs bone marrow mesenchymal cell fate. *Cell Metab* (2017) 25:661–72. doi: 10.1016/j.cmet.2017.01.001
- Iwaniec UT, Turner RT. Failure to generate bone marrow adipocytes does not protect mice from ovariectomy-induced osteopenia. *Bone* (2013) 53:145–53. doi: 10.1016/j.bone.2012.11.034
- Matsumoto Y, La Rose J, Lim M, Adissu HA, Law N, Mao X, et al. Ubiquitin ligase RNF146 coordinates bone dynamics and energy metabolism. *J Clin Invest* (2017) 127:2612–25. doi: 10.1172/JCI92233
- Xiao Z, Baudry J, Cao L, Huang J, Chen H, Yates CR, et al. Polycystin-1 interacts with TAZ to stimulate osteoblastogenesis and inhibit adipogenesis. *J Clin Invest* (2018) 128:157–74. doi: 10.1172/JCI93725
- Yu B, Huo L, Liu Y, Deng P, Szymanski J, Li J, et al. PGC-1 α controls skeletal stem cell fate and bone-fat balance in osteoporosis and skeletal aging by inducing TAZ. *Cell Stem Cell* (2018) 23:193–209.e5. doi: 10.1016/j.stem.2018.06.009
- Zou W, Rohatgi N, Brestoff JR, Li Y, Barve RA, Tycksen E, et al. Ablation of fat cells in adult mice induces massive bone gain. *Cell Metab* (2020) 32:801–813.e6. doi: 10.1016/j.cmet.2020.09.011
- Baum T, Rohrmeier A, Syväri J, Diefenbach MN, Franz D, Dieckmeyer M, et al. Anatomical variation of age-related changes in vertebral bone marrow composition using chemical shift encoding-based water-fat magnetic resonance imaging. *Front Endocrinol (Lausanne)* (2018) 9:141. doi: 10.3389/fendo.2018.00141
- Justesen J, Stenderup K, Ebbesen EN, Mosekilde L, Steiniche T, Kassem M. Adipocyte tissue volume in bone marrow is increased with aging and in patients with osteoporosis. *Biogerontology* (2001) 2:165–71. doi: 10.1023/a:1011513223894
- Di Iorgi N, Rosol M, Mittelman SD, Gilsanz V. Reciprocal relation between marrow adiposity and the amount of bone in the axial and appendicular skeleton of young adults. *J Clin Endocrinol Metab* (2008) 93:2281–6. doi: 10.1210/jc.2007-2691
- Shen W, Chen J, Punyanitya M, Shapses S, Heshka S, Heymsfield SB. MRI-Measured bone marrow adipose tissue is inversely related to DXA-measured bone mineral in Caucasian women. *Osteoporos Int* (2007) 18:641–7. doi: 10.1007/s00198-006-0285-9
- Shen W, Scherzer R, Gantz M, Chen J, Punyanitya M, Lewis CE, et al. Relationship between MRI-measured bone marrow adipose tissue and hip and spine bone mineral density in African-American and Caucasian participants: the CARDIA study. *J Clin Endocrinol Metab* (2012) 97:1337–46. doi: 10.1210/jc.2011-2605
- Wren TA, Chung SA, Dorey FJ, Bluml S, Adams GB, Gilsanz V. Bone marrow fat is inversely related to cortical bone in young and old subjects. *J Clin Endocrinol Metab* (2011) 96:782–6. doi: 10.1210/jc.2010-1922
- Newton AL, Hanks LJ, Davis M, Casazza K. The relationships among total body fat, bone mineral content and bone marrow adipose tissue in early-pubertal girls. *Bonekey Rep* (2013) 2:315. doi: 10.1038/bonekey.2013.49
- Griffith JF, Yeung DK, Ma HT, Leung JC, Kwok TC, Leung PC. Bone marrow fat content in the elderly: a reversal of sex difference seen in younger subjects. *J Magn Reson Imaging* (2012) 36:225–30. doi: 10.1002/jmri.23619
- Aaron N, Kraakman MJ, Zhou Q, Liu Q, Costa S, Yang J, et al. Adipsin promotes bone marrow adiposity by priming mesenchymal stem cells. *Elife* (2021) 10:e69209. doi: 10.7554/eLife.69209
- Tencerova M, Figeac F, Ditzel N, Taipaleenmäki H, Nielsen TK, Kassem M. High-fat diet-induced obesity promotes expansion of bone marrow adipose tissue and impairs skeletal stem cell functions in mice. *J Bone Miner Res* (2018) 33:1154–65. doi: 10.1002/jbmr.3408
- Beck L, Leroy C, Salaün C, Margall-Ducos G, Desdouets C, Friedlander G. Identification of a novel function of Pit1 critical for cell proliferation and independent of its phosphate transport activity. *J Biol Chem* (2009) 284:31363–74. doi: 10.1074/jbc.M109.053132
- Beck L, Leroy C, Beck-Cormier S, Forand A, Salaün C, Paris N, et al. The phosphate transporter Pit1 (Slc20a1) revealed as a new essential gene for mouse liver development. *PLoS One* (2010) 5:e9148. doi: 10.1371/journal.pone.0009148
- Byskov K, Jensen N, Kongsfelt IB, Wiesel M, Pedersen LE, Haldrup C, et al. Regulation of cell proliferation and cell density by the inorganic phosphate transporter Pit1. *Cell Div* (2012) 7:7. doi: 10.1186/1747-1028-7-7
- Couasnay G, Bon N, Devignes CS, Sourice S, Bianchi A, Véziers J, et al. Pit1/Slc20a1 is required for endoplasmic reticulum homeostasis, chondrocyte survival, and skeletal development. *J Bone Miner Res* (2019) 34:387–98. doi: 10.1002/jbmr.3609
- Forand A, Beck L, Leroy C, Rousseau A, Boitez V, Cohen I, et al. EKLf-driven PIT1 expression is critical for mouse erythroid maturation *in vivo* and *in vitro*. *Blood* (2013) 121:666–78. doi: 10.1182/blood-2012-05-427302
- Kongsfelt IB, Byskov K, Pedersen LE, Pedersen L. High levels of the type III inorganic phosphate transporter Pit1 (SLC20A1) can confer faster cell adhesion. *Exp Cell Res* (2014) 326:57–67. doi: 10.1016/j.yexcr.2013.01.004
- Liu L, Sánchez-Bonilla M, Crouthamel M, Giachelli C, Keel S. Mice lacking the sodium-dependent phosphate import protein, Pit1 (SLC20A1), have a severe defect in terminal erythroid differentiation and early b cell development. *Exp Hematol* (2013) 41:432–43.e7. doi: 10.1016/j.exphem.2013.01.004
- Ma XX, Li X, Yi P, Wang C, Weng J, Zhang L, et al. Pit2 regulates neuronal outgrowth through interaction with microtubule-associated protein 1B. *Sci Rep* (2017) 7:17850. doi: 10.1038/s41598-017-17953-3

30. Salaün C, Leroy C, Rousseau A, Boitez V, Beck L, Friedlander G. Identification of a novel transport-independent function of Pit1/SLC20A1 in the regulation of TNF-induced apoptosis. *J Biol Chem* (2010) 285:34408–18. doi: 10.1074/jbc.M110.130989
31. Beck-Cormier S, Lelliott CJ, Logan JG, Lafont DT, Meramtdjian L, Leitch VD, et al. Slc20a2, encoding the phosphate transporter Pit2, is an important genetic determinant of bone quality and strength. *J Bone Miner Res* (2019) 34:1101–14. doi: 10.1002/jbmr.3691
32. Yamada S, Wallingford MC, Borgeia S, Cox TC, Giachelli CM. Loss of Pit-2 results in abnormal bone development and decreased bone mineral density and length in mice. *Biochem Biophys Res Commun* (2018) 495:553–9. doi: 10.1016/j.bbrc.2017.11.071
33. Kerckhofs G, Stegen S, van Gastel N, Sap A, Falgayrac G, Penel G, et al. Simultaneous three-dimensional visualization of mineralized and soft skeletal tissues by a novel microCT contrast agent with polyoxometalate structure. *Biomaterials* (2018) 159:1–12. doi: 10.1016/j.biomaterials.2017.12.016
34. Beekman KM, Zwaagstra M, Veldhuis-Vlug AG, van Essen HW, den Heijer M, Maas M, et al. Ovariectomy increases RANKL protein expression in bone marrow adipocytes of C3H/HeJ mice. *Am J Physiol Endocrinol Metab* (2019) 317: E1050–4. doi: 10.1152/ajpendo.00142.2019
35. Carpenter AE, Jones TR, Lamprecht MR, Clarke C, Kang IH, Friman O, et al. CellProfiler: image analysis software for identifying and quantifying cell phenotypes. *Genome Biol* (2006) 7:R100. doi: 10.1186/gb-2006-7-10-r100
36. Boxall SA, Jones E. Markers for characterization of bone marrow multipotential stromal cells. *Stem Cells Int* (2012) 2012:975871. doi: 10.1155/2012/975871
37. Rostovskaya M, Anastasiadis K. Differential expression of surface markers in mouse bone marrow mesenchymal stromal cell subpopulations with distinct lineage commitment. *PLoS One* (2012) 7:e51221. doi: 10.1371/journal.pone.0051221
38. Ambrosi TH, Scialdone A, Graja A, Gohlke S, Jank AM, Bocian C, et al. Adipocyte accumulation in the bone marrow during obesity and aging impairs stem cell-based hematopoietic and bone regeneration. *Cell Stem Cell* (2017) 20:771–784.e6. doi: 10.1016/j.stem.2017.02.009
39. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2⁻(delta delta C(T)) method. *Methods* (2001) 25:402–8. doi: 10.1006/meth.2001.1262
40. Bravenboer N, Bredella MA, Chauveau C, Corsi A, Douni E, Ferris WF, et al. Standardised nomenclature, abbreviations, and units for the study of bone marrow adiposity: Report of the nomenclature working group of the international bone marrow adiposity society. *Front Endocrinol (Lausanne)* (2019) 10:923. doi: 10.3389/fendo.2019.00923
41. Sulston RJ, Cawthorn WP. Bone marrow adipose tissue as an endocrine organ: close to the bone. *Horm Mol Biol Clin Investig* (2016) 28:21–38. doi: 10.1515/hmbci-2016-0012
42. Baryawno N, Przybylski D, Kowalczyk MS, Kfoury Y, Severe N, Gustafsson K, et al. A cellular taxonomy of the bone marrow stroma in homeostasis and leukemia. *Cell* (2019) 177:1915–1932.e16. doi: 10.1016/j.cell.2019.04.040
43. Helbling PM, Piñeiro-Yáñez E, Gerosa R, Boettcher S, Al-Shahrour F, Manz MG, et al. Global transcriptomic profiling of the bone marrow stromal microenvironment during postnatal development, aging, and inflammation. *Cell Rep* (2019) 29:3313–3330.e4. doi: 10.1016/j.celrep.2019.11.004
44. Schwalie PC, Dong H, Zachara M, Russeil J, Alpern D, Akkiche N, et al. A stromal cell population that inhibits adipogenesis in mammalian fat depots. *Nature* (2018) 559:103–8. doi: 10.1038/s41586-018-0226-8
45. Tikhonova AN, Dolgalev I, Hu H, Sivaraj KK, Hoxha E, Cuesta-Domínguez Á, et al. The bone marrow microenvironment at single-cell resolution. *Nature* (2019) 569:222–8. doi: 10.1038/s41586-019-1104-8
46. Scheller EL, Doucette CR, Learman BS, Cawthorn WP, Khandaker S, Schell B, et al. Region-specific variation in the properties of skeletal adipocytes reveals regulated and constitutive marrow adipose tissues. *Nat Commun* (2015) 6:7808. doi: 10.1038/ncomms8808
47. Bon N, Frangi G, Source S, Guicheux J, Beck-Cormier S, Beck L. Phosphate-dependent FGF23 secretion is modulated by Pit2/Slc20a2. *Mol Metab* (2018) 11:197–204. doi: 10.1016/j.molmet.2018.02.007
48. Lecka-Czernik B, Stechschulte LA, Czernik PJ, Sherman SB, Huang S, Krings A. Marrow adipose tissue: Skeletal location, sexual dimorphism, and response to sex steroid deficiency. *Front Endocrinol (Lausanne)* (2017) 8:188. doi: 10.3389/fendo.2017.00188
49. Wu Y, Xie L, Wang M, Xiong Q, Guo Y, Liang Y, et al. Mettl3-mediated m⁶A RNA methylation regulates the fate of bone marrow mesenchymal stem cells and osteoporosis. *Nat Commun* (2018) 9:4772. doi: 10.1038/s41467-018-06898-4
50. Abuduli M, Ohminami H, Otani T, Kubo H, Ueda H, Kawai Y, et al. Effects of dietary phosphate on glucose and lipid metabolism. *Am J Physiol Endocrinol Metab* (2016) 310:E526–38. doi: 10.1152/ajpendo.00234.2015
51. Ayoub JJ, Samra MJ, Hlais SA, Basil MS, Obeid OA. Effect of phosphorus supplementation on weight gain and waist circumference of overweight/obese adults: a randomized clinical trial. *Nutr Diabetes* (2015) 5:e189. doi: 10.1038/nutd.2015.38
52. Basil MS, Obeid OA. Phosphorus supplementation recovers the blunted diet-induced thermogenesis of overweight and obese adults: A pilot study. *Nutrients* (2016) 8:E801. doi: 10.3390/nu8120801
53. Billington EO, Gamble GD, Bristow S, Reid IR. Serum phosphate is related to adiposity in healthy adults. *Eur J Clin Invest* (2017) 47:486–93. doi: 10.1111/eci.12769
54. Eller P, Eller K, Kirsch AH, Patsch JJ, Wolf AM, Tagwerker A, et al. A murine model of phosphate nephropathy. *Am J Pathol* (2011) 178:1999–2006. doi: 10.1016/j.ajpath.2011.01.024
55. Imi Y, Yabiki N, Abuduli M, Masuda M, Yamanaka-Okumura H, Taketani Y. High phosphate diet suppresses lipogenesis in white adipose tissue. *J Clin Biochem Nutr* (2018) 63:181–91. doi: 10.3164/jcbn.17-141
56. Obeid OA. Low phosphorus status might contribute to the onset of obesity. *Obes Rev* (2013) 14:659–64. doi: 10.1111/obr.12039
57. Park W, Kim BS, Lee JE, Huh JK, Kim BJ, Sung KC, et al. Serum phosphate levels and the risk of cardiovascular disease and metabolic syndrome: a double-edged sword. *Diabetes Res Clin Pract* (2009) 83:119–25. doi: 10.1016/j.diabres.2008.08.018
58. Ko FC, Martins JS, Reddy P, Bragdon B, Hussein AI, Gerstenfeld LC, et al. Acute phosphate restriction impairs bone formation and increases marrow adipose tissue in growing mice. *J Bone Miner Res* (2016) 31:2204–14. doi: 10.1002/jbmr.2891
59. Ko FC, Kobelski MM, Zhang W, Grenga GM, Martins JS, Demay MB. Phosphate restriction impairs mTORC1 signaling leading to increased bone marrow adipose tissue and decreased bone in growing mice. *J Bone Miner Res* (2021) 36:1510–20. doi: 10.1002/jbmr.4312
60. Jensen N, Autzen JK, Pedersen L. Slc20a2 is critical for maintaining a physiologic inorganic phosphate level in cerebrospinal fluid. *Neurogenetics* (2016) 17:125–30. doi: 10.1007/s10048-015-0469-6
61. Wallingford MC, Gammill HS, Giachelli CM. Slc20a2 deficiency results in fetal growth restriction and placental calcification associated with thickened basement membranes and novel CD13 and laminin α 1 expressing cells. *Reprod Biol* (2016) 16:13–26. doi: 10.1016/j.repbio.2015.12.004
62. Meramtdjian L, Beck-Cormier S, Bon N, Couasnay G, Sourice S, Guicheux J, et al. Expression of phosphate transporters during dental mineralization. *J Dent Res* (2018) 97:209–17. doi: 10.1177/0022034517729811
63. Suchacki KJ, Morton NM, Vary C, Huesa C, Yadav MC, Thomas BJ, et al. PHOSPHO1 is a skeletal regulator of insulin resistance and obesity. *BMC Biol* (2020) 18:149. doi: 10.1186/s12915-020-00880-7
64. Yadav MC, Simão AM, Narisawa S, Huesa C, McKee MD, Farquharson C, et al. Loss of skeletal mineralization by the simultaneous ablation of PHOSPHO1 and alkaline phosphatase function: a unified model of the mechanisms of initiation of skeletal calcification. *J Bone Miner Res* (2011) 26:286–97. doi: 10.1002/jbmr.195

COPYRIGHT

© 2022 Frangi, Guicheteau, Jacquot, Pyka, Kerckhofs, Feyeux, Veziers, Guihard, Halgand, Sourice, Guicheux, Prieur, Beck and Beck-Cormier. This is an open-access article distributed under the terms of the [Creative Commons Attribution License \(CC BY\)](#). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.